Method for the production of activated marked tumor-specific T cells and use thereof in treatment of tumors

A method of treating a tumor in a patient, comprising the steps of:

• (A) obtaining tumor cells from said patient,
• (B) inhibiting proliferation of said tumor cells and incubating said tumor cells with reagents comprising a ternary complex consisting essentially of
• i) a biotinylated antibody against a cell surface antigen of said tumor cells from said patient or at least two Fab fragments of said antibody,
• ii) a ligand which is avidin, streptavidin or neutravidin, and
• iii) biotinylated B7-Ig,
• (C) obtaining T cells from said patient, and thereafter
• (D) co-cultivating said tumor cells of step (B) with said T cells to activate said T cells in the presence of at least interleukin 2, and thereafter
• (E) isolating T cells from said tumor cells to obtain MHC-restricted, activated tumor-specific T cells, and thereafter
• (F) administering an effective amount of said MHC-restricted, activated tumor-specific T cells to said patient.

A method for producing MHC-restricted, activated tumor-specific T cells, comprising the following steps:

• (1) obtaining tumor cells from a patient;
• (2) inhibiting the proliferation of the tumor cells and conducting a three-step procedure:
• I. incubating said tumor cells with a biotinylated antibody against a cell surface antigen of said tumor cells from said patient or at least two Fab fragments of said antibody to obtain a product of step I;
• II. incubating the product of step I with a ligand which is avidin, streptavidin or neutravidin to obtain a product of step II;
• and
• III. incubating the product of step II with biotinylated B7-Ig to generate targeted tumor cells;
• (3) obtaining T cells from said patient;
• (4) co-cultivating said targeted tumor cells with said T cells to activate said T cells in the presence of at least interleukin 2;
• and thereafter
• (5) isolating said T cells from the targeted tumor cells to obtain activated tumor-specific T cells.

A method of treating tumors in a patient, comprising the following steps:

• (A) obtaining tumor cells from said patient;
• (B) inhibiting the proliferation of said tumor cells and conducting a three-step procedure:
• I. incubating said tumor cells with a biotinylated antibody against a cell surface antigen of said tumor cells from said patient or at least two Fab fragments of said antibody to obtain a product of step I;
• II. incubating the product of step I with a ligand which is avidin, streptavidin or neutravidin to obtain a product of step II;
• and
• III. incubating the product of step II with biotinylated B7-Ig to generate targeted tumor cells;
• (C) obtaining T cells from said patient;
• (D) co-cultivating said targeted tumor cells with said T cells to activate said T cells in the presence of at least interleukin 2;
• and thereafter
• (E) isolating said T cells from said targeted tumor cells to obtain MHC-restricted, activated tumor-specific T cells, and thereafter
• (F) administering an effective amount of said MHC-restricted, activated tumor-specific T cells to said patient.